New ‘game-changer’ tests for endometriosis given green light on NHS
New ‘Game-Changer’ Tests for Endometriosis Approved for NHS Use
New game changer tests for endometriosis - For years, women in the UK have faced lengthy journeys to uncover the truth behind their endometriosis symptoms, often enduring multiple visits to general practitioners and even emergency departments before a definitive diagnosis. That may soon change with the National Institute for Health and Care Excellence (Nice) endorsing two novel diagnostic tools—EndoSure and Endotest—for NHS implementation. These innovations are expected to significantly reduce the average time to diagnosis, which currently exceeds nine years for many patients.
Non-Invasive Approaches to Faster Detection
Endotest, one of the approved methods, involves collecting a saliva sample from patients, which is then analyzed in a laboratory for specific microRNA markers linked to endometriosis. This process provides results to healthcare providers within a short timeframe, enabling quicker decision-making. Meanwhile, EndoSure utilizes sensor pads placed on the abdomen to detect electrical signals in the gut, which are associated with the condition. Unlike Endotest, which requires a saliva sample, EndoSure involves a brief preparation period where patients fast for six to eight hours before drinking water for 45 minutes to ensure accurate readings.
The approval of these tests marks a pivotal moment in the fight against delayed diagnosis, a challenge that has long plagued women suffering from endometriosis. This chronic condition, characterized by the growth of womb-like cells in other parts of the body, causes severe pain and can disrupt daily activities, relationships, and professional life. Despite its prevalence—approximately 10% of women of reproductive age in the UK are affected—many remain undiagnosed for over a decade.
Nice emphasized that the tests are not standalone solutions but are designed to complement existing diagnostic methods. They are particularly useful when symptoms persist despite normal clinical exams or inconclusive imaging results such as ultrasounds and MRIs. The approval is valid for three years, during which time further evidence on the tests’ efficacy will be gathered. This period allows for refinement and ensures robust data before full-scale NHS integration.
Real-Life Impact: Stories of Delay and Relief
Ami Robertson, a 23-year-old Pilates instructor from Glasgow, shared her experience of enduring symptoms for over seven years. Initially diagnosed with irritable bowel syndrome, she described feeling dismissed by medical professionals. “I spent years being told my pain was something else entirely,” she said. “I started to doubt myself, wondering if it was all in my head.” Her breakthrough came after undergoing the Endotest, which delivered results in under an hour. “For the first time, I was believed, and I could finally get the help I needed,” she added. “Today my quality of life is night and day compared to before. No one should have to wait years to be believed.”
Simran Chavda, a 15-year-old from Huddersfield, also endured a prolonged struggle with endometriosis. Her severe pelvic pain began at age 13, yet repeated visits to GPs and emergency departments failed to pinpoint the cause. “Getting my diagnosis honestly felt like the best thing in the world,” she said. “It gave me a sense of relief I had never known before.”
These personal accounts highlight the emotional toll of delayed diagnoses. According to a survey conducted by the All-Party Parliamentary Group on endometriosis, over half of the 10,000 participants reported visiting their GP more than 10 times before receiving a confirmed diagnosis. Additionally, many had to seek care at A&E due to worsening symptoms. Such delays often stem from factors like limited access to specialist services and the complexity of identifying endometriosis through traditional imaging techniques.
The new tests aim to address these challenges by offering non-invasive alternatives. Endotest’s saliva-based approach eliminates the need for more invasive procedures, while EndoSure’s use of abdominal sensors provides a painless method to assess gut-related indicators. Both tests are expected to streamline the diagnostic process, allowing primary care teams to act swiftly and confidently. However, Nice noted that a third technology, DotEndo, requires additional research before it can be recommended for NHS use.
Expert Insights on the Path Forward
Dr. Anastasia Chalkidou, healthtech programme director at Nice, underscored the importance of these advancements. “A diagnosis of endometriosis can take some women the best part of a decade,” she explained. “The UK average is nine years and four months, and for those from ethnically diverse communities, it can extend to 11 years. This delay means living with chronic pelvic pain that affects daily life, relationships, and work.”
Dr. Chalkidou praised the potential of the new technologies to empower healthcare professionals with better tools for early identification. “These innovations offer primary care teams a way to detect endometriosis without relying solely on imaging or invasive procedures,” she said. “Our draft guidance reflects our commitment to delivering promising treatments quickly while ensuring rigorous validation before broader adoption.”
The approval of EndoSure and Endotest is seen as a major step forward by researchers and patient advocates. Endometriosis remains a complex condition to diagnose, as symptoms can overlap with other health issues. Ultrasound scans, MRIs, and laparoscopies—where a camera is inserted through a small abdominal incision—are the current gold standards. However, these methods are not always accessible immediately, and their accuracy can vary depending on the expertise of the operator.
With the introduction of these tests, there is hope that more women will receive timely diagnoses and access to effective treatment. The reduced waiting times could lead to earlier interventions, potentially improving outcomes and alleviating long-term suffering. As Nice continues to collect evidence, the broader NHS community will have the opportunity to evaluate and adopt these tools, marking a shift toward more efficient and compassionate care for endometriosis patients.
These advancements not only offer a lifeline to individuals like Ami and Simran but also signal a transformation in how endometriosis is approached in the UK healthcare system. By integrating innovative technologies, the NHS aims to ensure that no woman has to wait years to gain a diagnosis and start her journey toward relief.